The directors of Queensland Bauxite Ltd (ASX:QBL) are excited to inform our shareholders that completion of the acquisition of 55% of MCL has occurred today with the issue of 49 million shares in QBL to the shareholders of MCL.
Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a manufacturing agreement with Hong Kong based Modern Dental Group. Modern Dental have extensive expertise in the manufacture of dental appliances and hold the required quality management certifications for medical device manufacture.
The daily commute from Geelong to Melbourne just got a little more perilous with a new study warning one fifth of Australian adults have fallen asleep while driving. Research from the Sleep Health Foundation also shows nearly a third of Australians drive while drowsy at least once a month. They're figures Geelong dentist Dr Joseph Juric said are only scratching the surface.
As the directors of Medical Cannabis Limited (MCL) are drafting a prospectus for an independent ASX listing of MCL, the Board of MCL in conjunction with the QBL (ASX:QBL) Board, have decided that the MCL Initial Public Offering (IPO) will be giving Queensland Bauxite shareholders preference to take up shares in the anticipated MCL Listing on ASX.
Andrew Kavasilas, Technical Director of Medical Cannabis Limited (MCL), has been interviewed by 2Ser 107.3 in relation to the work that he has been doing with Medical Cannabis Limited and Vitahemp, and in preparation for the upcoming Hemp Health and Innovation Expo, Australia's largest Cannabis Expo. Andrew also discussed general information on the industry and Cannabis.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Japanese Patent Office has issued a decision to grant a key patent covering the composition, manufacture and use of Progenza stem cell technology.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability.
